Molina Healthcare at UBS Global Healthcare Conference - MOLINA HEALTHCARE INC

Financial Performance:

• Projected 2026 earnings per share (EPS) building blocks start at $9.50, derived from a $5.25 base, $4.00 in new "embedded earnings" (non-legacy), and $0.75 from stabilizing Marketplace losses, partially offset by $0.20–$0.25 in California UIS headwinds.
• 2026 premium revenue expected to grow $3 billion to $45 billion; this growth is projected to drive $1.50 in G&A efficiency gains through leverage.
• Medicaid Medical Loss Ratio (MLR) guidance is 92.6% for 2026; any improvement beyond this threshold directly increases the $9.50 EPS baseline.
• Current business margins are approximately 1% to 1.5%, remaining positive despite industry-wide losses; the company targets a return to 2.5% strategic margins in the future.
• Balance sheet is robust with $600 million in cash at the parent level and debt-to-capitalization under 45%.

Guidance and Future Outlook:

• Management expresses "cautious optimism" for 2027, estimating earnings of at least $9.50 before MLR improvements, with a glide path to higher earnings in 2028–2029.
• Full-year guidance for 2027 is not yet formalized but is expected to be disclosed in February; earnings are typically 55–70% front-loaded.
• $4.00 of the $9.00 embedded earnings target will be realized in 2027, driven by Florida Kids reaching break-even ($1.50), exiting the loss-making general MAPD Medicare business ($1.00), and G&A leverage ($1.50).
• Long-term goals include reaching 2.5% margin targets during the strategic planning period.

Business Segments and Product Lines:

• Medicaid: Implementing new eligibility rules (OB3) with an anticipated 6% membership headwind in 2027; core medical trend is stable at 4.5%, with total trend projected at 5.5–6.0% due to acuity shifts.
• Medicare: Business will be strictly dual-eligible in 2027, leveraging "Enhanced Alignment Enrollment" (EAE) to gain a competitive advantage over competitors without Medicaid footprints; C-SNPs are viewed as temporary workarounds for non-dual players.
• Florida Kids: Launched October 1st; Q4 expected to show a 99% MLR and 5% pre-tax loss (adjusted to 97% MLR/3% loss after one-time reserves); path to break-even set for 2027.
• Marketplace (ACA): Contracting footprint to 7 states in 2027 (5 with meaningful scale) due to risk pool volatility; growth is contingent on market stability and local scale.
• M&A Pipeline: Actively tracking distressed non-profit plans; M&A strategy remains a priority following organic growth.

Market and Competitive Landscape:

• Medicaid markets are collectively underfunded by approximately 300 basis points; states are expected to incorporate rate increases to address this and anticipated trend increases.
• Competitive advantage in Duals is strengthened by the shift toward strong-form EAE, which favors integrated Medicaid/Medicare players like Molina over standalone Medicare plans.
• State procurement processes increasingly require reference checks on performance in other states, favoring Molina's track record over theoretical proposals.
• Post-election political environment (Democratic majority) may lead to relaxation of OB3 work requirements, though legislative gridlock in the Senate could limit federal changes.

Risks and Challenges:

• Membership Volatility: Uncertainty surrounding OB3 work requirements and biannual redeterminations could result in a 1–1.5% membership decline, impacting margins.
• California Regulation: Transition of undocumented immigration status members (UIS) back to fee-for-service in 2027 poses a $0.20–$0.25 per-share headwind.
  Regulatory Volatility: Persistent instability in the ACA marketplace (subsidies, enrollment rules) remains a barrier to investment.
• Acquisition Timing: Delays in Georgia and Texas contract implementations have pushed these revenues into the 2028 outlook, though readiness costs are already budgeted.

Management Commentary and Tone:

• Tone is confident yet cautious, emphasizing that the company is "in a trough" in 2026 but positioned for recovery in 2027.
• Management distinguishes "embedded earnings" as incremental opportunities (acquisitions/RFPs) rather than legacy business improvements.
• Leadership asserts that the company's disciplined cost management allows for G&A efficiency gains even during revenue contraction or stabilization.
• Confidence in the dual-eligible strategy is high, noting that Molina outperforms the market by ~300 basis points.

Analyst Questions and Answers:

• Embedded Earnings Composition: Clarified that the $9 target is purely incremental (e.g., Florida Kids, MAPD exit, G&A leverage) and does not include legacy margin improvements.
• Florida Ramp-Up: Explained that the initial Q4 loss is driven by one-time reserves and startup inefficiencies; the path to break-even involves medical cost improvements and G&A optimization.
• EAE and CSNPs: Confirmed that Enhanced Alignment Enrollment (EAE) applies only to duals, making C-SNPs a workaround for plans lacking Medicaid contracts; predicted states will move toward strong-form EAE.
• Capital Allocation: Reiterated the pecking order of organic growth (50% ROE), M&A, and share repurchases; no capital constraints exist due to strong cash positions.
• Election Impact: Noted potential state-level flexibility on work requirements due to Democratic governor wins, though federal gridlock may limit major legislative changes.

Other Key Points:

• MLR improvement is a key upside lever; if Medicaid MLR exceeds 92.6% in 2026, the EPS target will exceed $9.50.
• The company retains 90% of re-procurements and wins 80% of new procurements, indicating strong operational execution.
• One-time costs associated with new revenue recognition (PFAD, LAE) significantly impact initial quarter reporting but are excluded from core operational performance.
• Market volatility is managed by focusing on "local scale" to ensure representative risk pools, particularly in the Marketplace segment.